Member Info for technick

Thanks CTW, what they say doesn't make sense in as much as the Novacyt test can run on any qPCR device including Genedrive and has everything in it from a reagent persepective

https://www.genesig.com/products/10039-coronavirus-covid-19-ce-ivd

I guess Genedrive are looking to MRC for funding to put a test onto the Genedrive platform because of fund availability but why not give the Genedrive to Novacyt and they could do the leg work. Genedrive just isn't flexible enough in my opinion and seem to prefer R&D to commercialisation.

... and before that blue you were telling everyone to buy. most of us did sell some at a profit, I sold my original investment so everything I hold here is profit, everyone has their own investment tactic and I for one never suggest people should buy or sell because everyones starting position is different. How can you possibly know when it makes sense for someone else to buy or sell?

From what I see the Genesig unit is a research machine and looking at the specs doesn’t seem to be a point of care system. As you say it looks to be research based and not designed for clinical use.

It’s a RT-PCR test and it looks to be designed to work on any PCR system so would run on a Genedrive. I’m not sure the NHS has sufficient lab capablabilty for large numbers of molecular tests. It’s not what they do. NCYTand Genedrive combined would allow testing pretty much anywhere...

in my opinion, like you I'm expressing an opinion and not for anyone to act on what I say!

Agree in large part. The relevance comes if as they suspect that the virus is spread before the onset of symptoms. In that scenario you need a very sensitive test and a molecular test would be the only sensitive option. The test currently used in screening is not sensitive and only good to confirm symptomatic patients. Where validators tests have been performed (ie in recovered patients who have tested positive again), the PCR based tests are used in the lab. It all depends where this goes next. If it does become pandemic then better screening tools will be needed in my opinion. Genedrive would allow outreach deployment out of the laboratory. But I just don't believe the company is on the case otherwise they would have already positioned Genedrive as a response device. It could be, DOD would be using it in this manner for biodefence. Genedrive just need to be a bit more savvy about the potential and not fixed in the old-school clinical modality - Genedrive is so much more

It would, but rude not to reply to shareholders who are underpinning and supporting the share price. If they are not doing anything (not suggesting they are) then they could have replied and said the business activities are detailed in the annual reports and RNSs and the Company continues with those activities. The communications from the business is awful and the CEO has not done any interviews for a while. He takes a large salary and is given a decent options package but isn't delivering shareholder value in my opinion. But I believe the business has a lot of potential and this recent requirement for rapid point of care testing with COVID-19 just goes to prove that. If they can do HCV then they can do COVID-19. Wake up Genedrive if you are reading the bulletin boards, partner with someone making the test and work it out. If you can't partner someone who can

wise words Srush

Agree Gee

You show your true colours, shame on you. Investment sometimes is about making a difference and supporting a business that is trying to bring something new to market. You show no soul and no support in your dealings here.

I think he is probably trying to insinuate that because of the issue with the COVID-19 and the poor people in Asia who are suffering as a result of what looks to be pandemic, that trade with those countries will suffer. That is not a very kind position to take and if true then I am happy to loose all my investment based on the tragedy that would need to unfold to get there.

not sure if the management have looked to partner one of the UK companies supplying PCR based coronavirus tests. The combination with Genedrive would be pretty compelling...

https://www.healthcareitnews.com/news/how-ai-and-machine-learning-are-transforming-clinical-decision-support

Having announced they are seeking a buyer or partner for StoneChecker on the 18th December I would suggest that the Company will be obligated to update the market well before the summer. My guess is that an update would be due at 3 months which would be by mid March. Let’s see...

#bekind

Any information that is not yet in the public domain, which could be considered price-sensitive and may have an impact on the share price, will prevent directors from trading shares in the business. The legalities around this are very strict and the trading window for directors is often fraught with difficulty.

Any discussion with a third party about the potential sale of part of a business (in this case StoneChecker) will create a closed period for Directors of the business. This is particularly true because the Company have previously announced their intention to approach Companies and Directors will now have a good idea of that the interest is and the type of transactions are possible, or equally not possible. Both are price sensitive. A deal does not have to be agreed to create a closed period. This is to prevent Directors benefiting from their insider information.

Hi Geeforce, I agree, they are in a closed period until they formally withdraw their stated intention since information either way is material.

If the directors are talking to perspective companies, which they are because they have publicly stated they are, then they are not allowed to buy or sell shares during the discussion period, it would be a closed period until they sate they are no longer looking to sell the product to a third party. Any discussion is material wither it is at an early or late stage.

Come on guys, they've announced they are looking for a buyer for the product so it's not speculation it's a consequence of the previous announcement if they have managed to move forward with their stated intent.